![ISPOR 2024 May 5-8, 2024 | Atlanta, GA, USA. Early Registration Rate expires March 28.]({"type":"image" , "src" : "/sda/112343/IJME-March-May.jpg"})
References
- World Health Organization (WHO). Global Strategy on Diet, Physical Activity and Health. Diabetes Facts. http://www.who.int/hpr/gs.fs.diabetes.shtml. Accessed February 16, 2012 (Copyright 2003)
- Centers for Disease Control and Prevention. National diabetes fact sheet: National estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. Accessed February 16, 2012
- American Diabetes Association (ADA). Diabetes Basics: Prevention, Risk Factors. http://www.diabetes.org/diabetes-basics/prevention/risk-factors/. Accessed February 16, 2012 (Copyright 1995--2012)
- Dall TM, Zhang Y, Chen YJ, et al. The economic burden of diabetes. Health Aff 2010;29:297-303
- Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335-42
- Gallwitz B. Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus. Treat Endocrinol 2005;4:361-70
- Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
- Pawaskar M, Zagar A, Sugihara T, et al. Healthcare resource utilization and costs assessment of type 2 diabetes patients initiating exenatide BID or glargine: a retrospective database analysis. J Med Econ 2011;14:16-27
- Misurski D, Lage MJ, Fabunmi R, et al. A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine. Appl Health Econ Health Policy 2009;7:245-54
- Lage MJ, Fabunmi R, Boye KS, et al. Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy. Adv Ther 2009;26:217-29
- Health Insurance Portability and Accountability Act (HIPAA), Pub. L. No. 104-191,110 Stat.1936 2006. Washington, DC, USA: US Department of Health and Human Services
- Lee WC, Conner C, Hammer M. Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States. Clin Ther 2010;32:1756-67
- Lau HS, de Boer A, Beuning KS, et al. Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol 1997;50:619-25